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Background
Sudden cardiac death (SCD) due to ventricular tachyarrhythmias is a significant contributor to mortality in heart disease patients accounting for approximately 300,000 deaths per year in the United States. 1 Defibrillation therapy, if delivered within minutes of the patient's collapse, provides the highest probability of surviving life-threatening ventricular tachyarrhythmias. 2 Implantation of an implantable cardioverter defibrillator (ICD) is associated with a significant reduction in all-cause mortality in at-risk cardiac patients. [2] [3] [4] However, appropriate selection prior to a decision for ICD implantation may be essential in several patient subsets, including patients with a transient risk for SCD; patients who do not meet current guideline indications for an ICD due to restrictions based on time from specific clinical events (e.g., myocardial infarction); 5 patients who previously have had an ICD removed because of complications or malfunction, patients who refuse an ICD, and patients with a suspected arrhythmic disorder who are still undergoing evaluation.
The Wearable Cardioverter Defibrillator (WCD) provides continuous arrhythmia monitoring, detection of arrhythmic cardiac arrest and automatic defibrillation with rapid detection of the potentially fatal ventricular tachyarrhythmia. The safety and effectiveness of the WCD in saving lives has been documented in publications including the first testing reported in 1998, 6 the WEARIT/BIROAD study in 2004, 7 and the first retrospective report in 2010. 8 The aim of the WEARIT-II Registry, the first prospective, observational registry on the WCD, was 1) to characterize the patients currently prescribed with a wearable cardioverter defibrillator, 2) to assess the risk for sustained ventricular tachyarrhythmic events among at-risk cardiac patients during the WCD use by the etiology of the disease, and 3) to identify the rate of ejection fraction improvement and the need for subsequent ICD implantation in high-risk cardiac patients ndications for an ICD due to restrictions based on time from specific clinical eve e ent nt nts s s (e (e (e.g .g .g., ., , myocardial infarction); 5 patients who previously have had an ICD removed because of comp mp mpli li lica ca cati ti tion on ons s or r r m m malfunction, patients who refu use se se a a an ICD, and patients s s wi w w th a suspected ar ar arrh h hythmic dis i or or or e d der w wh who o o ar ar are e e st st stil il ill l l un un unde de derg rg r oing ng g e e evalu ua a atio o on. n. n.
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Methods

Study population
All patients who wore a medically prescribed Wearable Cardioverter Defibrillator (LifeVest® system, ZOLL, Pittsburgh, USA) were offered participation in the Registry through a letter included at the time of dispensing the WCD. Current indication for use of the WCD has been outlined earlier. 9 In short, patients with low ejection fraction and a high risk for sudden cardiac death after myocardial infarction, following coronary revascularization, with a new onset dilated 
Wearable Cardioverter Defibrillator
The commercially available market-released WCD devices were used in the WEARIT-II Registry. The WCD is composed of a garment containing three self-gelling defibrillation patch non-ischemic cardiomyopathy, with high risk for sudden cardiac death until stabili iza za zati t on on on, , , or or or w w with nherited or congenital heart disease patients are prescribed WCD. Patients who agre re re d d ed t t to particip p pate were e ent n ered into the Registry after writte t n informed consent t. . Patients were expected o o o re e eceive uni ni nifo orm rm rm, cu cu urr rr rren en ent t t gu guid id idel el elin in ine e in in indi d d ca ca ate te ted d d car re inclu lu ludi di ding ng ng m m med ed edic ic ical al a t t the he herapy y y a a and nd nd m man an nag ag agem em emen en ent, an an nd d d th t e Regist st s ry ph hysi i ici ians we we were not o o inv n nvolve ed d d in a an n ny m m med ed edic ic cal l l ca ar re e e of th h he sub ub ubje e ects. T Th he h University y y of Rochester was the Coordination and Data Center ( ( (CDC) ) ) for the WEARIT-II electrodes, two on the back and one in the front, and four non-adhesive ECG electrodes connecting to a monitoring unit that weighs about 0.77 kg.
The WCD continuously monitors the patient's heart rhythm and can automatically deliver up to 5 posterior-anterior defibrillation shocks. Once an arrhythmia is detected, an alarm sequence starts with a silent vibration and is followed by an escalating audible siren alarms. The device detection algorithm incorporates three inputs: heart rate, template matching, and 
Arrhythmia events
An arrhythmic episode included an onset and a conversion to a slower and regular rhythm. Any arrhythmia episode that was separated by 5 minutes from the previous one was considered a separate episode. Each individual arrhythmia episode was reviewed and adjudicated in the registry and classified into four major categories: 1. Sustained ventricular tachycardia (VT, lasting 30 seconds or longer) or ventricular fibrillation (VF) with WCD shock therapy, 2.
Sustained VT with no WCD shock delivered, due to use of the response buttons, 3. Nonsustained VT of less than 30 seconds of duration, or 4. Atrial fibrillation (AF) or supraventricular tachycardia (SVT) properly detected by the device. Inappropriate WCD therapy was classified as non-VT/VF episodes detected and treated by a WCD shock.
Statistical analysis
Continuous 
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Baseline clinical characteristics
Clinical characteristics of the Registry patients by disease etiology are listed in Table 1 . The median age of the study patients was 62 years (IQR: 16). Patients with ischemic etiology were older than patients with non-ischemic and congenital/inherited heart disease (p-value for the overall difference < 0.001). The proportion of women was highest among patients with nonischemic cardiomyopathy (36%) and lowest among those with ischemic cardiomyopathy (23%).
The median ejection fraction was 25%, with relatively lower EF in the non-ischemic group (20%) than in the ischemic (26%) or in the congenital/inherited sub-groups (23%, p-value for the overall difference < 0.001). About half of the study patients reported heart failure (HF) symptoms at baseline. Medical therapy was similar in patient sub-groups. Patients with congenital/inherited heart disease were more likely to have a history of atrial fibrillation, while those with ischemic heart disease were more likely to have a history of sudden cardiac arrest (SCA) (11%) or syncope (23%) prior to WCD use.
Among patients with congenital/inherited disease, the most common etiology was congenital heart disease reported in 61%, followed by inherited heart disease (53%), such as hypertrophic cardiomyopathy (25%), arrhythmogenic right ventricular dysplasia (23%), long QT syndrome (10%) and Brugada syndrome (1%), allowing for multiple diagnoses at initial assessment.
Compliance
Median duration of WCD use was 90 days (IQR: 65), and median daily use was 22.5 hours (IQR: 2.69) in the total patient population (Figure 1A) . There was no significant difference in the daily use among the sub-groups of ischemic, non-ischemic or congenital/inherited heart disease (Supplemental Figure 1) . 
Arrhythmic events
A total number of 120 sustained VT/VF events occurred in 41 patients ( Table 2) , corresponding to a rate of 22 sustained episodes per 100 patient-years. Notably, most sustained VTs were not treated by the WCD because the patient used the response button to delay therapy and subsequently the VTs self-terminated. Specifically, 90 sustained VT events in 22 patients were withheld from therapy, whereas 30 events in 22 patients required WCD shock therapy due to hemodynamic instability (corresponding to 5 events per 100 patient years). All patients who required shock delivery had their VT/VF episodes successfully terminated with the first shock.
The event rate for non-sustained ventricular tachycardia (NSVT) and atrial tachyarrhythmias (SVT/AF) was 30 per 100 patient-years and 101 per 100 patient-years respectively ( Table 2) .
The rate of inappropriate WCD therapy was very low; only 10 patients (0.5 %, 2 per 100 patient years) had inappropriate WCD therapy during the follow-up due to ECG artifacts.
Inappropriate shocks did not induce ventricular tachycardia or ventricular fibrillation.
When the cumulative probability of sustained VT/VF was assessed by disease etiology, patients with ischemic and congenital/inherited heart disease were shown to have significantly higher probabilities of VT/VF than those with non-ischemic cardiomyopathy. In particular, at 3 months of follow-up, the rate of sustained VTs was 3% among patients with both ischemic cardiomyopathy and congenital/inherited heart disease, compared to 1% among those with nonischemic cardiomyopathy (p=0.02 for the overall difference among the 3 groups; Figure 2A) . 
Decision making after end of WCD use
At the end of WCD use, an ICD was implanted in 36% of patients with non-ischemic cardiomyopathy, in 42% of the ischemic patients, and in 46%of patients with congenital/inherited heart disease (Figure 3A) . The most frequent reason not to implant an ICD following the use of the WCD was improvement in ejection fraction (41%).
Arrhythmia and WCD therapy events during WCD use facilitated the decision of whether to implant an ICD at the end of use. Among patients who had appropriate therapy while using the WCD, 85% received an ICD (Figure 3B) . Likewise, the majority of patients (65%) with sustained non-treated VT received an ICD, while less than half of the patients with atrial arrhythmias or without arrhythmias were implanted with an ICD.
Of the 2000 patients who had the WCD, three (0.2%) died during WCD wearing. All three patients demonstrated an asystole event. None of the patients with VT or VF episodes died while wearing the WCD.
Discussion
WEARIT-II is the first prospective registry of the WCD to evaluate the safety and efficacy of the WCD as for the prevention of SCD in a real world setting during a time-period of risk assessment. We enrolled and prospectively followed 2000 patients with ischemic cardiomyopathy, non-ischemic cardiomyopathy or congenital/inherited heart disease prescribed the WCD due to increased risk for SCD.
Our findings from the WEARIT-II Registry provide several important clinical implications on the use of the WCD as a bridging strategy in these high risk populations: 1) WCD, 85% received an ICD (Figure 3B) . Likewise, the majority of patients (65% % %) ) ) wi wi with th th In our study, we extended these findings by collecting prospective data on a large cohort of patients. We had a detailed arrhythmia episodes report with the arrhythmia events reviewed and adjudicated in each case. Asystole was less frequent in our cohort, with only 3 patients developing it (0.2%). Furthermore, in our study, for the first time, we evaluated patient compliance, the risk of arrhythmic events, and end of use decisions by disease etiology. We found that disease etiology does not influence compliance, and patients with congenital/ inherited heart disease who are younger have similar compliance. In addition, we found important differences in VT/VF risk by disease etiology.
In WEARIT-II, there were a total of 120 sustained VT/VF events corresponding to 22 events per patient year. However the majority of these VT/VF events were self-terminating during the extended detection time. In order to evaluate whether the rate of sustained ventricular tachyarrhythmias among patients currently prescribed a WCD is comparable to those implanted with an ICD, we performed an analysis to compare the rate of VT/VF in the first 3 months in WEARIT-II, to patients enrolled in Multicenter Automatic Defibrillator Implantation Trial -Reducing Inappropriate Therapy (MADIT-RIT). MADIT-RIT consisted of patients with an ICD indication who were randomized to either a high-rate cut-off (Arm B), or delayed VT therapy (Arm C of the trial), both similar to current WCD programming. 10 We observed a 3-month, overall 2% cumulative probability of sustained treated or non-treated VT/VF in WEARIT-II, which was even higher than the 1% event rate of VT or VF rate in MADIT-RIT. This suggests that WEARIT-II enrolled patients were at a higher risk for SCD ( Supplemental Figure 2A and   B) . Importantly, in WEARIT-II the episodes of VT/VF were evenly distributed during the first three months of WCD use.
In WEARIT-II, there were a total of 120 sustained VT/VF events correspo o ond nd ndin in ing g g to to to 2 2 22 2 2 events per patient year. However the majority of these VT/VF events were self-terminating Assessing the risk of VT/VF events by disease etiology, we found that VT/VF risk was high among patients with ischemic cardiomyopathy, and congenital/inherited heart disease. The rate of sustained VT/VF events in the non-ischemic population of WEARIT-II was lower compared to the ischemic population in the registry, but comparable to patients with nonischemic cardiomyopathy and an implanted transvenous ICD enrolled in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial. 11 Furthermore, the risk for the occurrence of life-threating arrhythmic events in patients with non-ischemic cardiomyopathy is highly unpredictable. 12 Therefore, there is a need for continuous monitoring and protection during the period of risk assessment for SCD in this patient population.
An important subset of the patients with ischemic cardiomyopathy, who showed a high rate of sustained VT/VFs, was prescribed the WCD following an acute MI. While a previous study on post-MI patients suggested that the risk of ventricular tachyarrhythmias is the highest in the first month 13 , in our study, we found a similar risk of VT/VF during the 3 months of WCD use. This finding further stresses the importance of appropriate risk protection for SCD in the early post-MI period in patients with left ventricular dysfunction.
In WEARIT-II, we demonstrated an excellent compliance that was similar in patient subgroups. The use of WCD use was safe, there was no death related to the WCD use itself.
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The strength of our analysis is that we have information on all patients until the end of their WCD use. We have received information on all patients who prematurely discontinued the use of WCD or died while wearing the WCD.
Our study has certain limitations. Participation in the Registry was on a voluntary basis, and more compliant patients may have been self-selected. Data on the number and characteristics of patients who declined enrollment in the study were not collected. Furthermore, the WCD detected atrial and ventricular arrhythmias only above the detection rate; thus arrhythmias below the detection rate are not available. However, slow VTs may be self-terminating and they may not carry clinical significance, as recently suggested by the MADIT-RIT trial. 10 Arrhythmia events were analyzed independently however there may be patients with multiple type of arrhythmia events. Furthermore, we do not have long-term follow-up data available beyond the time period of WCD use (median of 90 days) at this point. Collection of long-term follow-up data on clinical outcome up to 12-months in WEARIT-II participants is currently ongoing.
In conclusion, this is the first prospective Registry on the Wearable Cardioverter Defibrillator, independent of the manufacturer, to demonstrate the safety and efficacy of the WCD in a large patient cohort with ischemic, non-ischemic and congenital/inherited heart disease. We found that the WCD successfully terminates ventricular tachyarrhythmias, and with the extended time to shock provided by the use of response buttons, many hemodynamically stable VTs spontaneously terminate. The compliance of wearing the WCD was very high, and unrelated to disease etiology. At the end of the WCD use, detected arrhythmias facilitated the decision whether to implant an ICD device. WCD could be used as a powerful risk prediction tool to identify patients with high-risk for SCD who benefit from implantation of an ICD. 
